Departed
Karen Walker
Director
LLY ·
ELI LILLY & Co
Karen Walker notified the Board of her resignation from the Board effective December 31, 2024.
Ready 8-Ks
23
Latest filing
May 20, 2026, 4:30 PM ET
Top materiality
0.85
Event mix
earnings ×10 · leadership ×6 · debt ×4
Sentiment
11 pos · 0 neg · 12 neu
Latest earnings
reported 2026-Q1
Executive change
recent →
Recent 8-K filings for LLY
Highest-materiality recent filing
Lilly Q1 revenue $19.8B (+56% YoY), raises FY guidance, FDA approves Foundayo
- Q1 2026 revenue $19.8B (up 56% YoY); reported EPS $8.26 (up 170%); non-GAAP EPS $8.55.
- FY2026 revenue guidance raised to $82B-$85B; non-GAAP EPS guidance $35.50-$37.00.
-
Lilly completes $9B multi-tranche debt offering tied to Centessa acquisition
Completed $9.0B aggregate principal debt offering across eight tranches of floating and fixed-rate notes due 2026-2066.
-
Lilly shareholders re-elect directors, reject board declassification and supermajority proposals
Four directors (Bertozzi, Kaelin, Moeller, Ricks) elected; say-on-pay approved with 95.7% of votes cast.
-
Lilly Q1 revenue $19.8B (+56% YoY), raises FY guidance, FDA approves Foundayo
Q1 2026 revenue $19.8B (up 56% YoY); reported EPS $8.26 (up 170%); non-GAAP EPS $8.55.
-
Lilly Q4 revenue up 43% to $19.3B; EPS $7.39 (+51%); FY2026 guidance $80-83B
Q4 revenue $19.3B (+43% YoY); reported EPS $7.39 (+51%); non-GAAP EPS $7.54 (+42%), both incl. $0.52 acquired IPR&D.
-
Eli Lilly elects Carolyn R. Bertozzi to board as independent director
Carolyn R. Bertozzi, Ph.D elected to board effective Dec 8, 2025; will stand for election at May 2026 annual meeting.
-
Lilly Q3 revenue up 54% to $17.6B; raises FY2025 guidance on Mounjaro/Zepbound demand
Q3 reported EPS $6.21 vs $1.07 YoY; non-GAAP EPS $7.02 vs $1.18.
-
Lilly raises $7.75B in multi-tranche debt offering; net proceeds ~$6.71B
Issued $7.75B across 7 tranches (floating-rate due 2028, fixed-rate due 2028-2065); closed Aug 20, 2025.
-
Lilly Q2 revenue $15.56B (+38% YoY), EPS $6.29 (+92%), raises FY guidance
Q2 revenue $15.56B, up 38% YoY, driven by volume growth from Zepbound and Mounjaro.
-
Lilly annual meeting: directors reelected, classified board and supermajority amendments fail
Four directors elected to three-year terms: Alvarez, Hedley, Johnson, Luciano, each with >726M votes for.
-
Lilly Q1 revenue up 45% to $12.73B; EPS beat; reaffirms guidance
Revenue $12.73B (+45% YoY) driven by Mounjaro and Zepbound volume growth.
-
Eli Lilly issues $6.5B of notes across 6 tranches; net proceeds ~$6.46B
Issues $1B 4.550% notes due 2028, $1.25B 4.750% notes due 2030, $1B 4.900% notes due 2032.
-
Lilly Q4 2024 revenue up 45% to $13.53B, EPS $4.88; 2025 guidance of $58-61B revenue
Q4 revenue $13.53B (+45% YoY); reported EPS $4.88 (+102%); non-GAAP EPS $5.32 (+114%).
-
Lilly updates 2024 revenue to ~$45B, Q4 ~$13.5B; guides 2025 revenue $58-61B
2024 full-year revenue expected ~$45.0B, up 32% YoY and $4B above initial guidance midpoint.
-
Eli Lilly elects P&G CEO Jon Moeller to board; Karen Walker resigns effective Dec 31
Jon Moeller, Chairman/CEO of Procter & Gamble, elected to Lilly board effective Dec 1, 2024.
-
Lilly Q3: Revenue $11.44B (+20% YoY); EPS $1.07/$1.18; FY revenue guidance raised to $45.4-$46.0B
Revenue $11.44B, up 20% YoY; excluding $1.42B prior-year olanzapine divestiture, revenue up 42%.
-
Lilly appoints Lucas Montarce as EVP and CFO, effective Sept 9, 2024
Lucas Montarce, 47, promoted from president of Spain/Portugal/Greece hub to CFO, effective immediately.
-
Lilly director Marschall S. Runge to retire from board effective Aug. 31, 2024
Runge served on board since 2013; retirement effective Aug. 31, 2024.
-
Eli Lilly issues $5B in notes across five tranches with maturities from 2027 to 2064
Issued $750M 4.150% notes due 2027, $1B 4.200% notes due 2029, $1.25B 4.600% notes due 2034, $1.25B 5.050% notes due 2054, $750M 5.200% notes due 2064.
-
Lilly Q2 revenue up 36% to $11.3B, raises FY revenue guidance by $3B
Q2 revenue $11.30B (+36% YoY); reported EPS $3.28 (+68%), non-GAAP EPS $3.92 (+86%).
-
Eli Lilly CFO Anat Ashkenazi resigns; Gordon Brooks interim CFO from July 15
Anat Ashkenazi resigned as EVP and CFO to pursue opportunity outside pharma; stays through July for transition.
-
Eli Lilly CFO Anat Ashkenazi resigns; to leave in July 2024
Anat Ashkenazi resigns as EVP and CFO to pursue a career opportunity outside the pharmaceutical industry.
-
Eli Lilly annual meeting: directors elected, governance amendments fail
All four director nominees elected; Katherine Baicker received 768.7M for, 4.8M against.
-
Lilly Q1 revenue up 26% to $8.77B; raises full-year guidance by $2B
Q1 reported EPS $2.48 (up 66% YoY); non-GAAP EPS $2.58 (up 59% YoY), including $0.10 acquired IPR&D charges.
Executive changes
Appointed
Lucas Montarce
executive vice president and chief financial officer
LLY ·
ELI LILLY & Co
elected Lucas Montarce, age 47, as executive vice president and chief financial officer
Departed
Marschall S. Runge
Director
LLY ·
ELI LILLY & Co
On August 13, 2024, Dr. Marschall S. Runge notified the Board of Directors (the "Board") of Eli Lilly and Company (the "Company") of his decision to retire from the Board, effective as of August 31, 2024.
Appointed
(interim)
Gordon Brooks
interim chief financial officer
LLY ·
ELI LILLY & Co
Effective July 15, 2024, Gordon Brooks, age 55, group vice president, controller and corporate strategy, of the Company, will assume the role of interim chief financial officer of the Company.
Departed
Anat Ashkenazi
executive vice president and chief financial officer
LLY ·
ELI LILLY & Co
On June 5, 2024, Eli Lilly and Company (the “Company”) announced that Anat Ashkenazi resigned as executive vice president and chief financial officer of the Company to pursue another career opportunity outside of the pharmaceutical industry.
Departed
Anat Ashkenazi
Executive Vice President and Chief Financial Officer
LLY ·
ELI LILLY & Co
Anat Ashkenazi resigned as Executive Vice President and Chief Financial Officer of the Company to pursue another career opportunity outside of the pharmaceutical industry.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.75 · Most common event earnings